Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

New tool aims to simplify vasectomy procedures

NCT ID NCT06891729

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study tested a new device called the Delivery Lumen Access Device (DLAD) in 24 healthy men who were already planning to have a vasectomy. The device is designed to help doctors access the vas deferens more easily. Researchers checked for side effects and how well the device worked during the procedure.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Delivery Lumen Access Device (DLAD)
What this could lead to
If it works, this device could make vasectomy procedures easier and safer for patients.
What could go wrong
This is a small, early-stage study with only 24 participants, so results may not apply to everyone. The device might still have unexpected risks.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

24 people

The number who actually took part.

Started

Mar 2025

Finished

Jun 2025

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 65 years

Sex

Male participants only

Healthy volunteers

Accepted

You do not need to have the condition being studied to take part.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: 1. Male subject who has already planned to undergo a vasectomy. 2. Male subject who has voluntarily signed and dated the Institutional Review Board (IRB)/Ethics Committee (EC) approved informed consent form (ICF) for this study before initiation of any screening or study-specific procedures. 3. 18 to 65 years of age at the time of consent. 4. Good health for undergoing a vasectomy procedure as confirmed by medical history and physical examination. 5. In the opinion of the Investigator, the subject is suitable to undergo a vasectomy procedure as a form of long-term contraception. Exclusion Criteria: 1. On exam, has any of the following: one or both vasa not present, abnormal scrotum, large varicocele, hydrocele, filariasis or elephantiasis of scrotum, or an intrascrotal mass that would make the subject not suitable for the study. 2. Prior testicular surgery, testicular injury, or prior vasectomy with vasovasostomy (vasectomy reversal). 3. Has local genital infections such as balanitis, scrotal skin infection, epididymitis, or orchitis, or tender (inflamed) tip of the penis, but may be enrolled after resolution of an acute infection. 4. History of prostatitis or benign prostatic hypertrophy requiring treatment. 5. Has known current coagulopathy or other bleeding disorders. 6. Known allergy to DLAD materials including nickel, stainless steel and silicone. 7. Has cystic fibrosis. 8. Has history of inguinal hernia repair. 9. The subject belongs to a vulnerable population. Vulnerable subject populations are defined as individuals who are incarcerated, handicapped, have cognitive challenges, mental disability, persons in nursing homes, children, impoverished persons, homeless persons, economically or educationally disadvantaged persons, nomads, refugees and those permanently incapable of giving informed consent. Vulnerable populations also may include members of a group with a hierarchical structure such as university students, subordinate hospital and laboratory personnel, employees of the sponsor, members of the armed forces and persons kept in detention. 10. Currently participating in another study involving an investigational device or drug within the last 30 days prior to the first screening. 11. Any site staff member with delegated study responsibilities or a family member of a site staff member with delegated study responsibilities. 12. In the opinion of the Investigator, there are issues or concerns that may compromise the safety of the subject or confound the reliability of compliance and information acquired in this study. 13. Has any condition that, in the opinion of the Investigator, would interfere with evaluation of DLAD product performance or interpretation of patient safety or study results.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Healthy male adults participants are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • Epworth HealthCare

    Melbourne, Victoria, 3002, Australia

  • VasectoPro

    Québec, Quebec/Canada, G1H7B5, Canada

More trials for these conditions

Other studies related to the condition(s) this trial covers.